Table 3.

Cause-specific Cox model

Association between dexamethasone use and occurrence of AKI in patients admitted in an ICU for severe COVID-19 infection. Results of cause-specific Cox models
	HR*	95 CI
Dexamethasone use (vs no use): Model 1	0.67	0.55–0.81
Model 2 (Model 1 adjusted for center)	0.76	0.62–0.92
Model 3 (Excluding patients with a delay of less than 12 h from the administration of DXM and the AKI)	0.62	0.49–0.77
Model 4 (Model 1 adjusted for wave rather than COVID variant)	0.75	0.57–1.00

Model 3: Results of a cause-specific Cox model excluding patients with a delay of less than 12 h from the administration of DXM and the AKI

Model 4: Results of a cause-specific Cox model adjusted for wave rather than COVID variant

*Adjusted for age (in years), sex (male/female), BMI (in kg/m²), CKD before ICU admission (yes vs no), hypertension before ICU admission (yes vs no), history of diabetes before ICU admission (yes vs no), immunodepression before ICU admission (yes vs no), invasive mechanical ventilation in the first 24 h (yes vs no), intravenous fluid therapy in the first 24 h (per L), Catecholamine use in the first 24 h (yes vs no), SAPS II (per unit), the COVID variant (Wuhan/Alpha/Beta/Gamma/Delta) or wave (1/2/3/4) (only for model 4) and center (model 2)

BMI body mass index, CKD chronic kidney disease, SAPS II simplified acute physiology score